nivolumab
bms
['nadim', 'nsclc', 'nivo', 'sclc']
pcr data from nadim in resectable stage iiia/b nsclc presented by dr. primary endpoint: pcr in itt pcr: 36.8% vs. 6.9% mpr: 52.6% vs. 13.8% both parameters clearly favoring the combination of nivo + chemo vs. chemo alone #asco22 
Oncologist taking care of people with cancer at Georgetown University | Father/husband/immigrant | #SoMeEditor @ClinicalLung | #LCSM